When both pre-treatment and on-treatment predictors were considered, in addition to a lower HBsAg at Week 24 (OR 0.247, 95% CI 0.149–0.408, P = <0.0001), only a higher baseline ALT (OR 1.213, 95% CI 0.977–1.505, P = 0.0806) was identified as additional weak predictor, but this did not reach statistical significance.
← all excerpts
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
1
—
—